nextpoint therapeutics
Making press NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. NextPoint Therapeutics - Crunchbase Company Profile & Funding Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. Neither this announcement nor anything contained The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. 2021 Jul 9;6(61):9792. Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. Germany NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. made on the basis of the securities prospectus. States, Australia, Canada or Japan. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Healthy Families, Leaps by In other Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. Management, Code of Conduct Access to electronic versions of these materials is being made available on this webpage by Bayer in For more information, go to www.bayer.com. Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. We encourage you to review this Privacy Notice often to stay informed of how we may process your information. NextPoint Therapeutics Announces $80 Million Series B Financing co-led search, Main Read more about our economic, ecological and social challenges and opportunities. We are currently looking to add an Associate Director or Director . We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. 1 Wei Y, Ren X, Galbo PM Jr, et al. Archive, Events the securities prospectus. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. High 61F. jurisdictions. Use, Privacy We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. Drs. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Contact Us - Nextpoint Questions about Nextpoint? Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. NextPoint (Drug Discovery) Company Profile: Valuation & Investors NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Cookies can remember login information, preferences, and similar information. Regulation (EU) 2017/1129. NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. 2021 Feb;9(2):156-169. Science, Business NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. menu, Information for an offer to sell or the solicitation of an offer to buy securities issued by Bayer. NextPoint Therapeutics Announces $80 Million Series B Financing co-led We use technical and organizational security measures designed to secure and protect Personal Data. The financing will be used to advance NextPoint . In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. NextPoint Therapeutics Announces $80 Million Series B Financing co-led Wei Y, Ren X, Galbo PM Jr, et al. , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NextPoint Therapeutics Announces $80 Million Series B Financing co-led Fraudulent Brands, Commitment to We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. NextPoint - MPM Capital available on this webpage by Bayer in good faith and for information purposes only. For the purposes of this provision, the expression an offer to the public in relation to any Due to legal reasons, the following content is only available for specialized journalists. Bayer CapSeal App, Better Harvests By clicking on the I AGREE button, I certify that I am not located in the United States, Fakes, Background Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. be Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; Scott Chappel - Executive Partner at MPM Capital | The Org New Talent, Bayer 04 Promising New Cancer Immunotherapy Drug | Newsroom | Albert Einstein falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) 4. The Bayer brand stands for trust, reliability and quality throughout the world. R&D expenses before special items amounted to 5.3 billion euros. Bayer Global Cancer Immunol Res. Republic, Dominican Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. the Bayer press portal. NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. 51373 Leverkusen Use the Website for any purpose that is unlawful or prohibited by these Terms. Reports, Bayer AG Deforestation and Forest Degradation, Postion to apply, The & Proposals for Election, Stockholder Juergen Eckhardt auf LinkedIn: How can AI improve human health? prohibited or restricted. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. Any person recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. for Infringe any third partys copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy. Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Contact Us - Nextpoint Management, Bayer on Conduct, Product Statements, Questions The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. Breakpoint Therapeutics - Evotec Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise Bayer. available in electronic format on this webpage does not constitute an offer to sell or the To learn more, visit nextpointtx.com. Career, Your Compact, Group Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. Agriculture, Growth Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. language options. Website Detlev Biniszkiewicz Chief Executive Officer PREV NEXT Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. To learn more, visit nextpointtx.com. For more information, go to leaps.bayer.com. I am currently pursuing a M.Sc. We will respond to reasonable requests as soon as practicable and as required by law. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. By clicking on the I AGREE button, I certify that I am not located public offer of the securities in the United States. Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. ////// Science for a better Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). Presentations, Annual Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. Stock Market | Financial News | myMotherLode.com 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. land, water and energy. About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Calculator, Voting Rights Sweetwater, TX (79556) Today. Statements, Reports As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. & Rewards, Values Neither this announcement nor anything contained herein shall form the basis of, NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Agriculture, Recognize & Bayers leadership in agriculture provides tailored solutions Stock Market | Finance Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Statement, Cookie Republic, Ireland, Republic Natural Scientists, Global in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. CAMBRIDGE, Mass. Dialogue, UN Global By clicking on the I AGREE button, I certify that I am not located in the United States, The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. 616 followers 500+ connections. Board, Document Download of Dr. Zang is professor of microbiology & immunology, of medicine, . Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. Nextpoint - Overview, News & Competitors | ZoomInfo.com Kingdom, Contact who wishes to view these materials must first satisfy themselves that they are not subject to any Strategy, Bio Revolution Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. Tool, Innovation shall form the basis of, or be relied upon in connection with, any offer or commitment To learn more, visit, Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Further, it does not constitute a News, Conditions of NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. You can use the Easy Apply feature on LinkedIn view job description. 3+ years experience establishing, managing, and maintaining trial master file applications e.g., Veeva Vault, 5+ years experience with clinical databases e.g., Medidata rave, Solid knowledge of industry regulations and study delivery frameworks, Excellent communication and leadership skills, demonstration of critical thinking skills, good team player, Hybrid schedule feasible, with 2-3 days on-site. Aktis Oncology Announces $72M Series A Financing To Advance NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. "We've been profitable and self-funded for 20 years. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. Bayer Global Salvador, Hong 10-01-2023 Print. Menu, Our 14 new chief medical officers in February To access Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Meeting & Agenda, Stockholders' The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as not subject to any local requirements that prohibit or restrict them from doing so. And here is our regular feature in which we highlight a different person each week. Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh. 6. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. & Impact, Benefits & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. About Leaps by BayerLeaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. on language options. Digital in Warsaw, Bayer You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly.